top
Please input keywords
Order
*Country
日本
アメリカ
中国
オーストラリア
シンガポール
イギリス
フランス
ドイツ
スイス
イタリア
カナダ
韓国
オランダ
ベルギー
スウェーデン
その他
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-1/hTIM3 mice
Strain Name
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Havcr2tm1(HAVCR2)Bcgen/Bcgen
Common Name  B-hPD-1/hTIM3 mice
Background C57BL/6 Catalog number  120524
Related Genes 
PD-1(Programmed death-1) ;
  HAVCR2
(hepatitis A virus cellular receptor 2)
NCBI Gene ID
18566,171285

mRNA expression analysis


from clipboard


Strain specific analysis of PD-1/TIM3 gene expression in WT and hPD-1/hTIM3 mice by RT-PCR. Mouse Pd-1/Tim3 mRNA were detectable in splenocytes of wild-type (+/+) mice. Human PD-1/TIM3 mRNA were detectable only in H/H but not in +/+ mice.


Protein expression analysis

from clipboard


Strain specific TIM3 expression analysis in homozygous B-hPD-1/hTIM3 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hTIM3 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-TIM3 antibody. Mouse TIM3 was detectable in WT mice. Human TIM3 was exclusively detectable in homozygous B-hPD-1/hTIM3 but not WT mice.


Protein expression analysis
from clipboard


Strain specific PD-1 expression analysis in homozygous B-hPD-1/hTIM3 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hTIM3 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-PD-1 antibody. Mouse PD-1 was detectable in WT mice. Human PD-1 was exclusively detectable in homozygous B-hPD-1/hTIM3 but not WT mice.


Combination Therapy of PD-1 mAb (Keytruda) and TIM3 mAb


from clipboard


Antitumor activity of anti-hTIM3 antibodies combined with anti-hPD-1 antibodies Keytruda in B-hPD-1/hTIM3 mice. (A) Anti-hTIM3 antibodies(Ab1/Ab2) combined with anti-hPD-1 antibodies Keytruda inhibited MC38 tumor growth in B-hPD-1/hTIM3 mice. Murine colon cancer MC38 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hTIM3 mice (female, 6-8 week-old, n=6). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-hTIM3 antibodies and anti-hPD-1 antibodies Keytruda with doses and schedules indicated in panel, (B) Body weight changes during treatment. As shown in panel A, combination of anti-hTIM3 Ab2 and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hTIM3 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hTIM3 antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.